Journal: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz

Article Title: SARS-CoV-2-Seroprävalenz bei Kindern und Jugendlichen in Deutschland – ein Überblick

doi: 10.1007/s00103-021-03448-0

Figure Lengend Snippet:

Article Snippet: CoKiBa : Coronavirus bei Kindern in Bayern ([ ]; 3 Regionen mit hohem, mittlerem und niedrigem Infektionsgeschehen) , Einladung aller Kinder mit einem Termin zu einer Vorsorgeuntersuchung 2020 in teilnehmenden Kinderarztpraxen , Elecsys Anti‑N Pan-Ig Roche, inhouse ELISA (RBD Anti-S-IgG) , 22.05.2020–22.07.2020 , 1815 Kinder, die 2020 zu einer Vorsorgeuntersuchung in teilnehmenden Kinderarztpraxen angemeldet waren (für die Auswertung nur jüngstes Kind pro Familie) , 1–14 , Tirschenreuth 7,2 %.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: BMC Cancer

Article Title: Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells

doi: 10.1186/1471-2407-13-41

Figure Lengend Snippet: Mean combination index values of NVP-AEW541 plus gemcitabine or afatinib in pancreatic cancer cell lines (three independent experiments)

Article Snippet: The anti-IGF-IR TKI NVP-AEW541 and pan-HER inhibitor afatinib were kindly provided by Novartis (Basel, Switzerland) and Boehringer Ingelheim respectively (Vienna, Austria) [ , ].

Techniques:

Journal: BMC Cancer

Article Title: Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells

doi: 10.1186/1471-2407-13-41

Figure Lengend Snippet: The effect of doubling dilutions (starting at 4xIC50 value followed by 8 doubling dilutions) of the combination of NVP-AEW541 and afatinib compared to single treatment, in (A) BxPc3 , (B) AsPc-1 cell lines.

Article Snippet: The anti-IGF-IR TKI NVP-AEW541 and pan-HER inhibitor afatinib were kindly provided by Novartis (Basel, Switzerland) and Boehringer Ingelheim respectively (Vienna, Austria) [ , ].

Techniques:

Journal: BMC Cancer

Article Title: Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells

doi: 10.1186/1471-2407-13-41

Figure Lengend Snippet: Effect of IGF-I, IGF-II, Insulin, EGF and NRG-1 at in the presence or absence of IGF-IR and/or HER inhibitors (400 nM) in BxPc3 (A) or FA6 (B) cell line (overnight starved). Cells were grown to near-confluency in 10% FBS growth medium, then treated with the inhibitors in 0.1% FBS growth medium at 37°C. Following 24 h incubation with the inhibitors or growth medium alone cells were stimulated with 20 nM of various growth factors for 15 min. Cells were lysed , protein samples were separated by SDS-PAGE, transferred onto PVDF membranes and probed with the antibodies of interest. C ). Effect of afatinib (400 nM) and NVPAEW541 (400 nM) when used alone or in combination in BxPc3 cells in 10% FBS growth medium.

Article Snippet: The anti-IGF-IR TKI NVP-AEW541 and pan-HER inhibitor afatinib were kindly provided by Novartis (Basel, Switzerland) and Boehringer Ingelheim respectively (Vienna, Austria) [ , ].

Techniques: Incubation, SDS Page